A Phase 3 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 37th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, and was the 12th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 32nd largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2020, is one of 8 in phase 3, and was the 25th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription. Participants do not need to be on active treatment. The purpose of this study is to gain a more complete understanding of the pathophysiology of the corneal events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained by performing impression cytology (IC) or superficial keratectomy (SK) procedure in participants treated with belantamab mafodotin. The procedure will only be performed in one eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic examination and composition analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with RRMM who have received or are currently receiving treatment with belantamab mafodotin and diagnosed with microcyst-like epithelial changes (MECs) on slit-lamp examination or confocal microscopy, with or without symptoms, in at least one eye.
a) If participants only had superficial punctate keratopathy with no evidence of MEC's they are not eligible.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
Drug: Belantamab mafodotin
SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
Drug: Belantamab mafodotin
Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin
Corneal tissue samples were collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.
Time frame: Up to approximately 23 months
Number of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin
Corneal tissue samples were collected to evaluate pathologic characteristics observed in participants treated with belantamab mafodotin.
Time frame: Up to approximately 23 months
Number of Participants With Imaging Data Showing Histopathologic Findings
The eye was visualized using a slit-lamp microscope in a procedure room.
Time frame: Up to approximately 23 months
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 23 months
The study has been terminated for reasons pertaining to feasibility.
| Milestone | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure |
|---|---|---|
| Started | 6 | 3 |
| Icsk population | 6 | 3 |
| Eicsk population | 4 | 2 |
| Completed | 6 | 3 |
| Not completed | 0 | 0 |
Corneal tissue samples were collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.
| Participants | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure |
|---|---|---|
| Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin | 4 | 2 |
Corneal tissue samples were collected to evaluate pathologic characteristics observed in participants treated with belantamab mafodotin.
| Participants | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure |
|---|---|---|
| Number of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin | 4 | 2 |
The eye was visualized using a slit-lamp microscope in a procedure room.
| Participants | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure |
|---|---|---|
| Number of Participants With Imaging Data Showing Histopathologic Findings | 2 | 3 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 0 | 0 |
Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to approximately 23 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Allocated to Undergo Impression Cytology Procedure | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Participants Allocated to Undergo Superficial Keratectomy Procedure | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Age, Continuous(Years) | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure | Total |
|---|---|---|---|
| Mean | 68.5 ± 9.05 | 71.3 ± 8.50 | 69.4 ± 8.44 |
| Sex: Female, Male(Participants) | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 3 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Participants Allocated to Undergo Impression Cytology Procedure | Participants Allocated to Undergo Superficial Keratectomy Procedure | Total |
|---|---|---|---|
| Not Hispanic or Latino | 6 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2020 to primary completion in Nov 2022, 23 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin